Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02056158 · ClinicalTrials.gov registry record
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 120
- Enrollment target
NCT02056158 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 120 participants.
The verdict
NCT02056158 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
In HIV+ cigarette smokers, with no prior history of pulmonary infections, emphysema is often developed at an earlier age and is a significant cause of morbidity despite treatment with antiretroviral drugs. Preliminary data gathered from HIV+ individuals that smoke cigarettes strongly support the hypothesis that the combination of HIV infection and smoking creates increased stress in the lower respiratory tract. To examine the underlying factors that contribute to the accelerated development of emphysema in this cohort, samples from the lower respiratory tract will be provided by HIV+ and HIV- subjects. The samples collected will serve as biomarkers for assessing the onset of emphysema.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-01-13 |
| Est. Completion | 2015-10-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02056158
The ClinicalTrials.gov registry entry for NCT02056158 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02056158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02056158 about?
NCT02056158 is a clinical study titled "HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium". In HIV+ cigarette smokers, with no prior history of pulmonary infections, emphysema is often developed at an earlier age and is a significant cause of morbidity despite treatment with antiretroviral drugs. Preliminary data gathered from HIV+ individuals that smoke cigarettes strongly support the hyp...
What is the current status of trial NCT02056158?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2014-01-13. Estimated completion is 2015-10-23.
Who is sponsoring clinical trial NCT02056158?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.